Souhaitez-vous accéder aux communiqués récents ?

Delivered quarterly net revenue of $13.7 million for Q1 2026 (11% increase from Q1 2025).Adjusted EBITDA1 loss of $0.6 million for Q1 2026 (compared to positive $0.7 million in Q1 2025) driven...

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued...

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after –  – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion...

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30,...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company...

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) --...

Planet Fitness Inquiry Alert: Investors with Losses after Cancellation Rates are Urged to Contact BFA Law about its Securities Investigation

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Digital Biomarkers Market by Type, Therapy, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.The...